Patient With HIV and Facial Lipoatrophy in Harmonization

Few situations in the facial harmonization clinic demand as much balance between technique and humanity as caring for people living with HIV. On one side, there is the clinical need to know the history, the immune status and the treatments. On the other, there is a history of stigma that leads many people to hide the diagnosis, avoid appointments or suffer veiled refusals. The practitioner who knows how to welcome, protect information and plan carefully delivers care that goes beyond the procedure.

This page is a review and does not replace follow-up with the infectious disease doctor. It includes no doses or injection technique. The ethical and legal side draws on consent and LGPD in photos and on LGPD (Brazil's data protection law), and general biosafety on biosafety in facial harmonization.

First principle: treat without discrimination

An HIV diagnosis is not a reason to refuse care. Refusing care for that reason can amount to discrimination, with ethical and legal consequences. In practical terms:

• Standard precautions for everyone. A safe clinic treats every patient with the same barriers, regardless of any diagnosis. Gloves, proper sharps disposal, asepsis and processing of materials are part of the routine, not an exception.
• No separate schedule or "special protocol" that exposes the patient. Additional biosafety measures should not create visible differences in treatment.
• No comments and no unnecessary curiosity. Information about the diagnosis matters for clinical planning, not for team conversation.

If for some reason the practitioner feels they are not the best person for a given procedure, the approach is to explain respectfully and refer, never to cite serostatus as the reason. See patient referral in facial harmonization.

What is HIV-associated facial lipoatrophy?

Facial lipoatrophy is the loss of subcutaneous fat in the face. In people with HIV, it was described mainly in those who used certain older treatment regimens, and it shows up as:

• Hollow temples and a reduced temporal fat pad.
• Flat or hollow cheeks, with loss of cheekbone projection.
• Marked nasolabial folds and a bony look to the face.
• Loss of volume around the mouth.

With modern therapies, lipoatrophy has become less common, but many patients live with after-effects from earlier years. Other causes of facial volume loss, such as weight loss, aging and illness, should be considered in the differential diagnosis. See facial volume loss after weight loss. The broader technical term is in facial lipodystrophy.

The emotional impact deserves attention: lipoatrophy can act as a "visible marker" of a condition the patient wants to keep private, which heightens the wish for correction and the sensitivity of the consultation.

Medical history and coordination with the infectious disease doctor

A good conversation starts with respect for privacy. Ask openly and let the patient decide what to share. Some useful points for planning:

1. Regular follow-up with an infectious disease doctor and regular use of treatment.
2. Immune status and viral load, as reported by the patient or the doctor, to understand how stable the condition is.
3. Other conditions: hepatitis, cardiovascular disease, diabetes, clotting disorders.
4. Medications in use, including potential interactions with anesthetics and other drugs. Assessing interactions is a medical task.
5. History of opportunistic infections or poor healing.
6. Previous procedures and products already used on the face, especially if the patient cannot name them. See patient with unknown previous filler.

When there is a clinical doubt about the safety of the procedure, respectful communication with the infectious disease doctor, with the patient's authorization, helps decide. The patient must authorize any contact. The general medical history is described in medical history in facial harmonization, and contraindications in general contraindications in facial harmonization.

Treatment planning

At review level, a few principles guide the plan for facial volume loss.

Assess by area and priority. Temples, cheekbone, folds and jawline are where lipoatrophy tends to stand out most. The priority should come from the patient's concern, not from a prefabricated list. See temple aging and midface aging.

Plan in stages. Gradual replacement, with reviews, lets you adapt to the tissue and lower the risk of overcorrection. Rushing does not help.

Consider the type of product. Reversible fillers and biostimulators are alternatives that are discussed, each with advantages and limitations. The literature describes the use of biostimulators in HIV-related lipoatrophy, and the choice should weigh the evidence, the labeled indication and the practitioner's experience. See biostimulators: overview and evidence on biostimulators.

Watch for infection risk. Rigorous asepsis is the rule for everyone. In patients with compromised immunity, any sign of infection should be taken seriously and assessed early. See infection and biofilm after filler.

Healing and bruising. Blood-related changes and medications can have an influence. Ask and observe. See expanding hematoma of the face.

Vascular risk is the same as for any patient. The danger zones remain the same. See vascular danger zones of the face.

Moderate expectations. The goal is to improve support and contour, without promising to erase the face's history.

Communication and welcome

Stigma is still a reality, and the patient may arrive on the defensive. Small gestures make a difference.

• Listen to the story attentively, without curiosity about how the diagnosis came about.
• Use respectful language: "person living with HIV", without labels.
• Guarantee privacy at the front desk, on forms and in messages. See explaining privacy to the facial harmonization patient.
• Explain what will be recorded, where and who will have access.
• Avoid unnecessary questions in front of companions or staff.
• Acknowledge the emotional impact of volume loss, without minimizing.

If the patient asks that something not be recorded, gently explain why the record matters for their safety and how it will be protected.

Confidentiality in clinic practice

Confidentiality is built in the details.

See also the clinic LGPD consent form template, which should be adapted with legal review and the rules of your professional board, and the patient image-use form template.

Universal biosafety, in brief

Without going into detailed protocols, the central points are the same for all patients:

• Hand hygiene and protective equipment as appropriate for the procedure.
• Single-use material disposed of properly. See sharps disposal and PGRSS.
• Processing of reusable items according to the rules. See sterilization of reusable materials.
• A plan for sharps injuries, known to the whole team. See sharps injury.
• Staff vaccination up to date. See hepatitis B and C and biosafety in facial harmonization.

Safety does not lie in knowing who does or does not have an infection, but in treating everyone as if they could.

In Harmy

Summary

Caring for people living with HIV in facial harmonization rests on three pillars: respect (no refusal and no differentiation), confidentiality (sensitive data protected) and planning (stages, partnership with the infectious disease doctor and universal biosafety). Facial lipoatrophy can be addressed with gradual replacement of volume and support, and listening to the patient is part of the treatment.